Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

• Forschungsstelle: INNOSUISSE
• Projektnummer: 101.972 IP-LS
• Projekttitel Englisch: Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

Schlüsselwörter (Englisch)

Life sciences, Pharmaceuticals

Abstract (Englisch)

Alentis Therapeutics AG is implementing unique anti-claudin 1 monoclonal antibodies as a novel approach for the treatment of liver fibrosis. This project aims at leveraging 3D-in vitro models to identify translational makers of target engagement.